According to BC subtypes, patients with TN-BC (133/139; 95.7%) presented most frequently with focal deficits compared to HR+ BC (187/213; 87.8%) and HER2+ BC (136/165; 82.4%; p = 0.005; chi-square test; Supplementary Table 3). The gene discussed is ERBB2; the disease is breast cancer.